.Charles Baum, M.D., Ph.D., that managed Mirati Therapies’ $ 5.8 billion sale to Bristol Myers Squibb in 2015, is taking the helm of young biotech Terremoto Biosciences.Baum’s “substantial expertise in medication progression, as well as effective record in advancing high-impact medications, are going to be instrumental,” outbound CEO Peter Thompson, M.D., mentioned in a July 25 launch. Thompson is going to retain his chair as panel chairperson..Baum, an experienced physician-scientist, was actually the creator, president and also chief executive officer of oncology-focused Mirati. Just before that, he aided build cancer medicines at Pfizer and also Schering-Plough..
Charles Baum, M.D., Ph.D.(( Mirati)).Now, Baum will serve as chief executive officer at Terremoto, a provider developing tiny molecules to target disease-causing healthy proteins– like those discovered in malignant lump cells– utilizing covalent bonds. Existing therapies that make use of covalent connections mostly target the amino acid cysteine. However, of the 20 amino acids that compose proteins, cysteine is actually the minimum usual.
Terremoto is instead targeting one of the necessary amino acids, amino acid lysine, which is actually located in nearly all healthy proteins.By targeting lysine as well as various other amino acids, Terremoto wants to treat previously undruggable ailments and also create first-in-class medications..The biotech, based in South San Francisco, raised $75 million in series A financing in 2022. A little more than a year later on, the biotech more than doubled that amount in a $175 million set B.